Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 lenvatinib vs placebo in 131I-refractory differentiated thyroid cancer
jRCT2080221533Phase 3
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in well-differentiated thyroid cancer (WDTC) comparing Lenvatinib 24 mg QD with Placebo (2 arms).
02
Drugs
lenvatinib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on jRCT2080221533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221533.